Ariceum Therapeutics GmbH
Industry
- Biotechnology
- Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Other Names/Subsidiaries
- Theragnostics Ltd.
Latest on Ariceum Therapeutics GmbH
In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of tre
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Antibiotics Firm Agrees To Go Private F
Despite the macroeconomic challenges that have beset the global life sciences sector, biotech firms in Switzerland together raised more than CHF1.3bn ($1.45bn) in 2022 according to the Swiss Biotech A
Venture capital firms that support biotechnology companies are raising billions of dollars to make new investments in 2023, but so far this year VC investors have invested conservatively in drug devel